Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEARI: Ribomunyl for Recurrent URTI in Children
NCT01948856Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Sep 2013
- Primary completion
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of Ribomunyl in recurrent upper respiratory tract infection (R-URTI), sponsored by Pierre Fabre Laboratories. Started Sep 2013; status: completed.
02
Drugs
Ribomunyl
03
Conditions
recurrent upper respiratory tract infection (R-URTI)
Beyond the preview
Go deeper on NCT01948856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01948856.